home / stock / ipha / ipha quote
Last: | $ |
---|---|
Change Percent: | 1.60% |
Open: | $7.75 |
Close: | $7.60 |
High: | $7.75 |
Low: | $7.57 |
Volume: | 5,364 |
Last Trade Date Time: | 02/12/2020 04:44:19 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $7.75 | $7.60 | $7.75 | $7.57 | 5,364 | 02-12-2020 |
$ | $7.5569 | $7.48 | $7.58 | $7.465 | 4,361 | 02-11-2020 |
$ | $7.53 | $7.4874 | $7.53 | $7.4874 | 587 | 02-10-2020 |
$ | $7.34 | $7.64 | $7.64 | $7.32 | 4,490 | 02-07-2020 |
$ | $7.4085 | $7.37 | $7.455 | $7.27 | 7,541 | 02-06-2020 |
$ | $7.33 | $7.25 | $7.352 | $7.25 | 543 | 02-05-2020 |
$ | $7.28 | $7.2084 | $7.3952 | $7.2084 | 1,328 | 02-04-2020 |
$ | $7.12 | $7.0438 | $7.2078 | $7.0438 | 2,311 | 02-03-2020 |
$ | $7.08 | $7.02 | $7.08 | $6.71 | 12,435 | 01-31-2020 |
$ | $6.98 | $6.90 | $6.9979 | $6.88 | 4,216 | 01-30-2020 |
$ | $7.29 | $7.1321 | $7.29 | $7.1321 | 634 | 01-29-2020 |
$ | $7.17 | $7.1768 | $7.1929 | $7.14 | 1,666 | 01-28-2020 |
$ | $7.26 | $7.01 | $7.2969 | $6.8201 | 6,759 | 01-27-2020 |
$ | $7.42 | $7.28 | $7.42 | $7.28 | 4,043 | 01-24-2020 |
$ | $7.5328 | $7.68 | $7.73 | $7.36 | 17,572 | 01-23-2020 |
$ | $7.71 | $7.60 | $7.71 | $7.50 | 14,246 | 01-22-2020 |
$ | $7.79 | $7.51 | $7.79 | $7.51 | 27,998 | 01-21-2020 |
$ | $7.62 | $7.605 | $7.6773 | $7.2501 | 15,658 | 01-20-2020 |
$ | $7.62 | $7.605 | $7.6773 | $7.2501 | 15,658 | 01-17-2020 |
$ | $7.33 | $7.27 | $7.35 | $7.27 | 16,545 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...